View More Recent Stories

May 28, 2019 07:30AM ProMIS Neurosciences Identifies Novel Antibodies for Alzheimer's Disease with Selectivity for the Neurotoxic Form of Tau
May 14, 2019 07:30AM ProMIS Neurosciences Announces First Quarter 2019 Results
Apr 23, 2019 07:30AM ProMIS Neurosciences to Participate in the Think Equity Investor Conference
Mar 26, 2019 07:30AM ProMIS Neurosciences to Participate in Microcap Spring Investor Summit 2019
Mar 21, 2019 02:47PM Aducanumab Failure: Selectivity for the Toxic Oligomer is Essential to Treating Root Cause of Alzheimer's Disease
Mar 19, 2019 07:30AM ProMIS Neurosciences to Present Data for Potential Best-in-Class Antibody Candidates for Parkinson's Disease at AD/PD™ 2019 Conference
Mar 15, 2019 07:30AM ProMIS Neurosciences Announces Fiscal Year 2018 Annual Results
Feb 21, 2019 07:30AM ProMIS Neurosciences Adds Pharmaceutical Leader Timothy Rothwell to Board of Advisors
Jan 31, 2019 07:30AM Selectivity for the Toxic Oligomer Essential to Treating Root Cause of Alzheimer's Disease
Jan 17, 2019 07:30AM ProMIS Neurosciences to Participate in NobleCon15 and CanTech Investment Conferences
Dec 18, 2018 07:30AM ProMIS Neurosciences to Present at Sachs Associates Neuroscience Innovation Forum and China Focus@JPMWeek
Nov 20, 2018 07:30AM ProMIS Neurosciences Issues Year-to Date Update, Highlighting 2018 Accomplishments
Nov 6, 2018 07:30AM ProMIS Neurosciences Discusses Critical Importance of Selectively Targeting the Root Cause of Alzheimer's Disease
Oct 11, 2018 07:30AM ProMIS Neurosciences Identifies Novel Antibody Drug Candidates for Parkinson's Disease
Sep 17, 2018 07:30AM ProMIS Neurosciences to Present at Extraordinary Futures Investment Conference
Aug 22, 2018 07:30AM ProMIS Neurosciences to Present at 20th Annual Global Investment Conference
Jul 10, 2018 07:30AM ProMIS Neurosciences to Present Preclinical Data on Alzheimer's Disease Therapeutic Antibody PMN310 at Alzheimer's Association International Conference
Jun 26, 2018 07:30AM ProMIS Neurosciences Unique Discovery Platform Generates Potential New Antibody Therapeutics for Neurodegenerative Diseases
Jun 20, 2018 07:30AM ProMIS Neurosciences Reminds Shareholders of June 25th Voting Cut-Off for Upcoming Annual General Meeting
May 1, 2018 07:30AM ProMIS Neurosciences Closes $7.2 Million Private Placement
Jan 25, 2018 07:30AM ProMIS Neurosciences Issues White Paper Entitled: "Not All Amyloid Beta Therapeutics Are Created Equal"
Dec 4, 2017 07:30AM ProMIS Neurosciences Announces Trading on OTCQB Venture Market
Oct 18, 2016 08:30AM StockNewsNow.com Publishes New SNNLive Video Interview with ProMIS Neurosciences, Inc. Providing Company Overview, Milestones for 2016-2017
View More Recent Stories